51
Participants
Start Date
November 6, 2017
Primary Completion Date
January 5, 2021
Study Completion Date
December 31, 2025
Niraparib
200 or 300 mg daily PO, for 21 day cycle
TSR-042
500 mg once intravenously on day 1 of cycle (From cycle 1-4 followed by 1000 mg intravenously every 6 weeks for maximum of 2 yrs)
Tom Baker Cancer Centre, Calgary
Juravinski Cancer Centre, Hamilton
Cancer Centre of Southeastern Ontario at Kingston, Kingston
London Regional Cancer Centre, London
Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto
Princess Margaret Cancer Centre, Toronto
McGill University Health Centre - Glen Site, Montreal
Tesaro, Inc.
INDUSTRY
University Health Network, Toronto
OTHER